+ All Categories
Home > Documents > DIA Then and Now: A Half-Century Odyssey · DIA Then and Now: A Half-Century Odyssey DIA was...

DIA Then and Now: A Half-Century Odyssey · DIA Then and Now: A Half-Century Odyssey DIA was...

Date post: 20-Jan-2021
Category:
Upload: others
View: 0 times
Download: 0 times
Share this document with a friend
1
DIA Then and Now: A Half-Century Odyssey DIA was founded by 30 pharmaceutical professionals, medical writers, and academics after they saw the Thalidomide issue as a global epidemic and saw the need for an organization that could foster cooperative efforts across the world. DIA holds stakeholder conferences on the need for specific, understandable, and accurate information in drug package inserts and publishes the Drug Information Journal (DIJ), DIA’s official peer-reviewed scientific publication. 1970’s DIA enters a period of global growth and expansion to support ICH and the scientific evaluation of medicines efforts, establishing formal offices in the US, Switzerland, and Japan. DIA members form a Community to define global data standards used in medical research, which leads to the formation of the Clinical Data Interchange Standards Consortium (CDISC). 1990’s DIA membership expands globally to over 80 countries, with local offerings to Latin America, Canada, Korea, China, India, the Middle East and Singapore. DIA relaunches Drug Information Journal as Therapeutic Innovation & Regulatory Science. 2000’s DIA takes the leadership role in examining clinical study methodology approaches; convenes international meetings; and facilitates the flow of information about regional practices and requirements for the International Registration Dossier. 1980’s DIA defines its thought leadership to span Translational Science and Medicine, Regulatory Science, Patient Engagement, and Value & Access. DIA recognized as an authorized training partner of the International Council on Harmonization (ICH). DIA facilitates China’s inclusion as official ICH member. DIA launches tailored programs such as GCP conference in India, Drug Discovery Innovation conference in China, and Medical Device conference in Japan. TODAY 1962 Congress enacted the Kefauver-Harris amendments to the Federal Food, Drug, and Cosmetic Act, which required that manufacturers prove the effectiveness of drug products before they go on the market, and afterwards report any serious side effects. 1964
Transcript
Page 1: DIA Then and Now: A Half-Century Odyssey · DIA Then and Now: A Half-Century Odyssey DIA was founded by 30 pharmaceutical professionals, medical writers, and academics after they

DIA Then and Now: A Half-Century Odyssey

DIA was founded by 30 pharmaceutical professionals, medical writers, and academics after they saw the Thalidomide issue as a global epidemic and saw the need for an organization that could foster cooperative e�orts across the world.

DIA holds stakeholder conferences on the need for specific, understandable, and accurate information in drug package inserts and publishes the Drug Information Journal (DIJ), DIA’s o­cial peer-reviewed scientific publication.

1970’sDIA enters a period of global growth and expansion to support ICH and the scientific evaluation of medicines e�orts, establishing formal o­ces in the US, Switzerland, and Japan. DIA members form a Community to define global data standards used in medical research, which leads to the formation of the Clinical Data Interchange Standards Consortium (CDISC).

1990’s

DIA membership expands globally to over 80 countries, with local o�erings to Latin America, Canada, Korea, China, India, the Middle East and Singapore. DIA relaunches Drug Information Journal as Therapeutic Innovation & Regulatory Science.

2000’s

DIA takes the leadership role in examining clinical study methodology approaches; convenes international meetings; and facilitates the flow of information about regional practices and requirements for the International Registration Dossier.

1980’s

DIA defines its thought leadership to span Translational Science and Medicine, Regulatory Science, Patient Engagement, and Value & Access. DIA recognized as an authorized training partner of the International Council on Harmonization (ICH). DIA facilitates China’s inclusion as o­cial ICH member. DIA launches tailored programs such as GCP conference in India, Drug Discovery Innovation conference in China, and Medical Device conference in Japan.

TODAY1962Congress enacted the Kefauver-Harris amendments to the Federal Food, Drug, and Cosmetic Act, which required that manufacturers prove the e�ectiveness of drug products before they go on the market, and afterwards report any serious side e�ects.

1964

Recommended